Picture of virus under microscope

Research under the microscope...

The Strathprints institutional repository is a digital archive of University of Strathclyde research outputs.

Strathprints serves world leading Open Access research by the University of Strathclyde, including research by the Strathclyde Institute of Pharmacy and Biomedical Sciences (SIPBS), where research centres such as the Industrial Biotechnology Innovation Centre (IBioIC), the Cancer Research UK Formulation Unit, SeaBioTech and the Centre for Biophotonics are based.

Explore SIPBS research

First dual aromatase-steroid sulfatase inhibitors

Woo, L.W.L. and Sutcliffe, O.B. and Bubert, C. and Grasso, A. and Chander, S.K. and Purohit, A. and Reed, M.J. and Potter, B.V.L. (2003) First dual aromatase-steroid sulfatase inhibitors. Journal of Medicinal Chemistry, 46 (15). pp. 3193-3196. ISSN 0022-2623

Full text not available in this repository. (Request a copy from the Strathclyde author)

Abstract

Aromatase inhibitors in clinical use block the biosynthesis of estrogens. Hydrolysis of estrone 3-sulfate by steroid sulfatase is an important additional source of tumor estrogen, and blockade of both enzymes should provide a more effective endocrine therapy. Sulfamoylated derivatives of the aromatase inhibitor YM511 inhibited sulfatase and aromatase in JEG-3 cells with respective IC50 values of 20-227 and 0.82-100 nM (cf. letrozole, 0.89 nM). One dual inhibitor was potent against both enzymes in vivo, validating the concept.